What is HC Wainwright’s Estimate for AURA Q1 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Aura Biosciences in a research report issued on Tuesday, August 11th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.40) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.41) EPS and Q4 2027 earnings at ($0.42) EPS.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10).

A number of other analysts have also weighed in on the stock. Wall Street Zen raised shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners set a $17.00 price objective on shares of Aura Biosciences in a research note on Tuesday, May 12th. Finally, Weiss Ratings raised Aura Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Aura Biosciences currently has a consensus rating of “Hold” and an average target price of $17.50.

Aura Biosciences Trading Up 4.4%

Aura Biosciences stock opened at $8.04 on Wednesday. The stock has a market cap of $831.66 million, a price-to-earnings ratio of -4.62 and a beta of 0.40. The company’s 50-day moving average price is $6.96 and its two-hundred day moving average price is $6.71. Aura Biosciences has a 52 week low of $4.73 and a 52 week high of $9.53.

Insider Buying and Selling

In other Aura Biosciences news, insider Anthony S. Gibney sold 12,824 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $6.42, for a total value of $82,330.08. Following the completion of the sale, the insider directly owned 265,354 shares of the company’s stock, valued at approximately $1,703,572.68. This represents a 4.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 1.90% of the company’s stock.

Institutional Trading of Aura Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in AURA. Parallel Advisors LLC lifted its stake in Aura Biosciences by 130.4% during the first quarter. Parallel Advisors LLC now owns 5,665 shares of the company’s stock valued at $38,000 after purchasing an additional 3,206 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after buying an additional 2,104 shares during the last quarter. ProShare Advisors LLC acquired a new position in Aura Biosciences in the fourth quarter worth approximately $59,000. Water Island Capital LLC bought a new position in shares of Aura Biosciences in the third quarter valued at $64,000. Finally, Invesco Ltd. bought a new position in shares of Aura Biosciences in the second quarter valued at $76,000. 96.75% of the stock is currently owned by institutional investors.

More Aura Biosciences News

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and set an $18 price target for Aura Biosciences (AURA). Although the target was reduced from $24, it still implies significant upside from the recently cited $8.04 share price. The firm expects ongoing quarterly losses of approximately $0.40 to $0.42 per share through 2027. Benzinga analyst target report
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests the available data does not indicate meaningful short-selling pressure, though the figures may reflect incomplete or anomalous reporting rather than a major change in investor positioning.
• Negative Sentiment: Aura reported a second-quarter 2026 loss of $0.48 per share, wider than the consensus estimate of a $0.38 loss. The earnings miss reinforces concerns about near-term cash burn and profitability. Aura Biosciences second-quarter earnings release
• Negative Sentiment: The company is cutting approximately 20% of its workforce and changing its executive leadership team as it refocuses research and development on eye-cancer programs. The restructuring may reduce expenses, but it also signals operational pressure and could raise execution concerns in the near term. Aura workforce reduction and R&D refocus

About Aura Biosciences

Aura Biosciences is a clinical?stage biopharmaceutical company focused on the development of novel virus?like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non?ophthalmic settings, leveraging precision activation via near?infrared light to induce localized tumor cell apoptosis and stimulate anti?tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.